GI Cancers

Barrett's Surveillance Shifts to a Risk-Based Footing

George Padron
Oncology Care, Biomarker & Genomic Testing, GI Cancers, Population Health Management | Jul 30, 2026
AGA's new Barrett's esophagus guideline replaces uniform surveillance with risk-based intervals and names high-quality endoscopy as the key to cancer prevention.

Glycemic Markers Contribute to The Obesity-Pancreatic Cancer Connection

Sonia Reyes
Oncology Care, Specialty Medicine, GI Cancers, Endocrinology & Metabolic, Managed Care, Population Health Management | Jul 24, 2026
In the UK Biobank study, glucose and HbA1c accounted for up to 20% of the link between obesity and pancreatic cancer, highlighting glycemic control as a modifiable target for prevention.

A First-of-Its-Kind RAS Inhibitor Lands in Pancreatic Cancer's Second Line

Sonia Reyes
Oncology Care, GI Cancers, Access & Affordability | May 31, 2026
ASCO 2026 plenary RASolute 302: oral daraxonrasib doubled median OS to 13.2 vs 6.7 months versus chemotherapy in previously treated metastatic pancreatic cancer

FDA Clears Daraxonrasib Expanded Access for Pretreated Metastatic Pancreatic Cancer

George Padron
Oncology Care, GI Cancers | May 1, 2026
FDA approved expanded access to the RAS inhibitor daraxonrasib for patients with previously treated metastatic pancreatic cancer just two days after Revolution Medicines requested it.

Advanced Cancer Treatment Creates New Reality of Living Long-Term With Terminal Disease

George Padron
Oncology Care, Breast Cancer, Hematologic Malignancies, GU Cancers, Lung & Thoracic, GI Cancers | Aug 27, 2025
Revolutionary cancer therapies enable patients to live years with terminal disease, requiring healthcare systems to adapt chronic care models.